by Proactive LTC Consulting | Jul 16, 2025 | 5-Star, Antipsychotics/Psychotropics, Behavioral Health, Compliance, F-Tag, Nursing, Psychotropics, Quality, Regulatory, Survey
F605 Gradual Dose Reduction Updates for Nursing Homes Earlier this year, the Centers for Medicare & Medicaid Services (CMS) issued revised guidance under F605, sharpening its focus on the misuse of psychotropic medications as chemical restraints and... by Proactive LTC Consulting | Jul 2, 2025 | 5-Star, Compliance, Regulatory, Staffing
PBJ Policy Manual & FAQs Updated PBJ Policy Manual Final – V2.7 – 06.30.2025 (PDF) PBJ Policy Manual FAQ 06.30.2025 (PDF) Updates were posted to the PBJ Policy Manual and FAQs on June 30, 2025. New Additions to the policy manual include:... by Proactive LTC Consulting | Jun 18, 2025 | Care Planning, Clinical, Compliance, QAPI, Regulatory, Survey
QAPI & Health Equity: What New Surveyor Guidance Means for Nursing Homes If you’ve worked in long-term care for more than a minute, you understand that QAPI is the backbone of quality improvement. But there’s a new layer added with the recent CMS... by Proactive LTC Consulting | Jun 4, 2025 | Care Planning, Compliance, Hospice, Regulatory
Q: Each skilled nursing facility arranging for the provision of hospice care under a written agreement must designate a member of the facility’s interdisciplinary team who is responsible for working with hospice representatives to coordinate care to the resident... by Proactive LTC Consulting | Jun 4, 2025 | Compliance, Elopement, Falls, Pressure Ulcers, QAPI, Quality, Regulatory, Survey
Learning from Adverse Events & Incidents Studies show that nearly one in three skilled nursing facility residents experience an adverse event during their stay, with approximately 60% of these events being potentially preventable. Adverse events in skilled... by Proactive LTC Consulting | May 28, 2025 | Clinical, Compliance, F-Tag, Pharmacy, Regulatory, Survey
Q: What are the most common reasons for the citing of F761 – Storage of Drugs and Biologicals? A: In Appendix PP the regulatory guidance for F761 is as follows: §483.45(g) Labeling of Drugs and Biologicals Drugs and biologicals used in the facility must be...